Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-29T16:41:53.787Z Has data issue: false hasContentIssue false

1127 – Evolution Of Addictive Comorbidities In a Group Of Patients Diagnosed With Schizophrenia During Atypical Antipsychotic Treatment

Published online by Cambridge University Press:  15 April 2020

D. Vasile
Affiliation:
University of Medicine and Pharmacy ‘Dr. Carol Davila’ Bucharest, Romania University Emergency Central Military Hospital ‘Dr. Carol Davila’ Bucharest, Romania
R.A. Macovei
Affiliation:
University of Medicine and Pharmacy ‘Dr. Carol Davila’ Bucharest, Romania Clinical Emergency Hospital Bucharest, Bucharest, Romania
O. Vasiliu
Affiliation:
University Emergency Central Military Hospital ‘Dr. Carol Davila’ Bucharest, Romania
A.G. Mangalagiu
Affiliation:
University Emergency Central Military Hospital ‘Dr. Carol Davila’ Bucharest, Romania
C. Tudor
Affiliation:
University Emergency Central Military Hospital ‘Dr. Carol Davila’ Bucharest, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Drug-related disorders are observed in 30–50% of the patients diagnosed with schizophrenia and is therefore an important problem to be adressed in clinical practice. There are many reasons for the overlap between addictive disorders and schizophrenia: the tendency to alleviate antipsychotic-related side effects, the need to decrease anxiety or depression, to interfere with sensory gating defficits etc.

Objective

To assess the effects of atypical antypsychotic treatment in decreasing the drug of abuse consumption in a population of schizophrenia diagnosed patients.

Methods

A group of 23 patients, diagnosed with schizophrenia and a drug related disorder (dependence 52.1%, polisubstance dependence 17.4%, substance abuse 26%, other 4.5%), according to DSM IV TR criteria, were monitored for 6 months, while being treated with atypical antipsychotics (olanzapine 43.4%, risperidone 34.7%, aripiprazole 17.4%, amisulpride 4.5%), using Positive and Negative Syndrome Scale for Schizophrenia (PANSS), Clinical Global Impressions (CGI) and Inventory of Drug Taking Situations (IDTS) every 4 weeks.

Results

The evolution of IDTS scores were not parallel to the PANSS evaluations: while the psychotic symptoms decreased continuously during the 6 months of the study (-40.5% at week 12 and -67.5% at endpoint), the IDTS decreased initially (- 33.2% at week 12) but increased slightly to the end of the study (-31.2% at endpoint). The CGI-I score has a decrease of 50.4% at week 12 and of 55.6% at week 24.

Conclusions

The evolution of drug related disorders during the atypical treatment of schizophrenia doesn’t correlate with the severity of psychosis and necessitates a specific management.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.